The fluctuating Parkinsonian patient--clinical and pathophysiological aspects.
Although levodopa-related motor response complications remain challenging from a pathophysiological and therapeutic standpoint, major advances have been made in the last decade, supporting the development of several promising drugs. Eventually, these drugs may help us to prevent, alleviate, or even "deprime" these frequent and disabling complications. Knowledge of the basic mechanisms and hypotheses underlying this fascinating conversion in the parkinsonian brain allows neurologists to understand the rationale behind emerging treatment strategies.
Blanchet
Pierre J
PJ
Department of Stomatology, Faculty of Dentistry, Universite de Montreal, Montreal, QC, Canada.
D000818:Animals; D004334:Drug Administration Schedule; D020820:Dyskinesias / Q000209:etiology* / Q000378:metabolism; D000882:Haplorhini; D006801:Humans; D007980:Levodopa / Q000008:administration & dosage / Q000009:adverse effects*; D010300:Parkinson Disease / Q000188:drug therapy*; D051381:Rats; D011954:Receptors, Dopamine / Q000378:metabolism; D018079:Receptors, GABA / Q000378:metabolism; D016194:Receptors, N-Methyl-D-Aspartate / Q000378:metabolism; D017981:Receptors, Neurotransmitter / Q000187:drug effects / Q000378:metabolism*; D011957:Receptors, Opioid / Q000378:metabolism
D011954:Receptors, Dopamine; D018079:Receptors, GABA; D016194:Receptors, N-Methyl-D-Aspartate; D017981:Receptors, Neurotransmitter; D011957:Receptors, Opioid; D007980:Levodopa